Pediatric Antifungal Utilization: New Drugs, New Trends
暂无分享,去创建一个
[1] J. Feinstein,et al. Shifting place of death among children with complex chronic conditions in the United States, 1989-2003. , 2007, JAMA.
[2] M. Maule,et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. , 2007, The New England journal of medicine.
[3] C. Feudtner,et al. Outcomes attributable to neonatal candidiasis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] C. Blyth,et al. Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review , 2007, Pediatrics.
[5] P. Smith,et al. Excess Costs of Hospital Care Associated With Neonatal Candidemia , 2007, The Pediatric infectious disease journal.
[6] F. Queiroz-Telles,et al. O141 Micafungin versus liposomal amphotericin B (AmBisome ®) in paediatric patients with invasive candidiasis or candidaemia , 2007 .
[7] T. Walsh,et al. Mycoses in pediatric patients. , 2006, Infectious disease clinics of North America.
[8] T. Walsh,et al. Epidemiology, Outcomes, and Costs of Invasive Aspergillosis in Immunocompromised Children in the United States, 2000 , 2006, Pediatrics.
[9] William Oh,et al. Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 Months , 2006, Pediatrics.
[10] D. Benjamin,et al. New antifungal agents under development in children and neonates , 2005, Current opinion in infectious diseases.
[11] A. Shad,et al. Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents , 2005, Antimicrobial Agents and Chemotherapy.
[12] J. Berlin,et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] W. Steinbach,et al. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation , 2005, Bone Marrow Transplantation.
[14] D. Benjamin,et al. Antifungal treatment in pediatric patients. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[15] W. Steinbach. Pediatric Aspergillosis: Disease and Treatment Differences in Children , 2005, The Pediatric infectious disease journal.
[16] T. Walsh,et al. New agents for invasive mycoses in children , 2005, Current opinion in pediatrics.
[17] T. Zaoutis. Risk Factors for Mortality in Children with Candidemia , 2004 .
[18] M. Karlsson,et al. Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.
[19] J. Perfect,et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.
[20] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[21] D. Kaufman,et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. , 2001, The New England journal of medicine.
[22] T D Koepsell,et al. Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services. , 2001, Pediatrics.
[23] L. Saiman,et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients , 2000, The Pediatric infectious disease journal.